Study guide
13.1 Diabetes Mellitus and the Periodontal Axis
Overseas Registration Examination ORE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: ORE Part 1 — Exam Blueprint, Logistics and Strategy
1.1 Structure and Format of ORE Part 1 1.2 The Official Blueprint and Preparing for Practice 1.3 Eligibility, Fees, Attempts and Time Limits
2 Chapter 2: Anatomy of the Head and Neck
2.1 The Trigeminal Nerve and Dental Innervation 2.2 The Facial Nerve and Parotid Region 2.3 The Temporomandibular Joint and Muscles of Mastication 2.4 The Infratemporal Fossa and Spread of Odontogenic Infection
3 Chapter 3: Dental Anatomy, Morphology and Occlusion
3.1 Permanent and Primary Tooth Morphology 3.2 Functional Occlusion: Centric Relation, Guidance and Interferences 3.3 Classifying Occlusion: Angle and BSI Incisor Relationships
4 Chapter 4: Genetics, Embryology and Odontogenesis
4.1 Stages of Odontogenesis and Molecular Signalling 4.2 Amelogenesis and Enamel Microstructure 4.3 Dentinogenesis and the Pulp-Dentine Complex 4.4 Cementum, the Periodontal Ligament and Oral Mucosa 4.5 Genetic and Developmental Dental Anomalies
5 Chapter 5: Oral Biology and Salivary Physiology
5.1 Salivary Gland Anatomy, Microarchitecture and Innervation 5.2 Salivary Secretion, Flow Rates and Autonomic Control 5.3 Salivary Buffering Systems and Protective Macromolecules 5.4 Physiology of Mastication and Deglutition 5.5 Taste, Lingual Papillae and Gustatory Pathways 5.6 Xerostomia, Sjogren's Syndrome and Salivary Diagnostics
6 Chapter 6: Physiology of the Major Body Systems
6.1 Cardiovascular and Respiratory Physiology 6.2 Renal, Endocrine and Gastrointestinal Physiology 6.3 Haematology and Haemostasis 6.4 Neurophysiology, Pain and the Autonomic Nervous System
7 Chapter 7: Bone Biology, Calcium Homeostasis and Healing
7.1 Microstructure and Architecture of Alveolar Bone 7.2 Bone Remodelling and the RANK/RANKL/OPG Axis 7.3 Endocrine Control of Calcium and Phosphate 7.4 Extraction Socket Healing and Ridge Resorption 7.5 Impaired Healing: MRONJ, Osteoradionecrosis and Systemic Risk
8 Chapter 8: Oral Microbiology and Biofilm Ecology
8.1 The Oral Microbiome and Biofilm Development 8.2 Cariogenic Microbiology: Mutans Streptococci and Lactobacilli 8.3 Ecological Hypotheses of Dental Caries 8.4 Biofilm Tolerance and the Case for Mechanical Plaque Control
9 Chapter 9: Immunology Relevant to Oral Disease
9.1 Innate Mucosal Immunity and Gingival Crevicular Fluid 9.2 Cellular Immunity in the Periodontium 9.3 Microbial Pathogenesis: Complexes and Keystone Pathogens 9.4 Host-Mediated Tissue Destruction 9.5 Hypersensitivity Reactions in Dental Practice 9.6 Autoimmune Mucocutaneous Bullous Disease 9.7 Immunodeficiency and Oral HIV Manifestations
10 Chapter 10: General Pathology and Neoplasia
10.1 Cellular Adaptation and Mechanisms of Cell Death 10.2 Inflammation, Wound Healing and Repair 10.3 Principles of Neoplasia and Carcinogenesis 10.4 TNM Staging of Oral Cavity Carcinoma
11 Chapter 11: Statistics and Research Methods
11.1 Study Designs and the Hierarchy of Evidence 11.2 Descriptive and Inferential Statistics 11.3 Diagnostic Test Performance 11.4 Critical Appraisal, Bias and Research Governance
12 Chapter 12: Human Disease: Cardiovascular and Respiratory
12.1 Infective Endocarditis and NICE CG64 12.2 Hypertension and Blood Pressure Thresholds for Dental Care 12.3 Angina, Myocardial Infarction and Antiplatelet Therapy 12.4 Asthma, COPD and Respiratory Emergencies
13 Chapter 13: Human Disease: Endocrine, Haematological and Renal
13.1 Diabetes Mellitus and the Periodontal Axis 13.2 Congenital Bleeding and Clotting Disorders 13.3 Anticoagulants and Antiplatelets: The SDCEP Protocol 13.4 Chronic Kidney Disease and Haemodialysis
14 Chapter 14: Human Disease: Gastrointestinal, Hepatic and Neurological
14.1 Gastrointestinal Disease and Intrinsic Dental Erosion 14.2 Liver Disease, Coagulopathy and Viral Hepatitis 14.3 Epilepsy, Stroke and Transient Ischaemic Attack 14.4 Trigeminal Neuralgia, Bell's Palsy and Giant Cell Arteritis
15 Chapter 15: Oral Aspects of Human Disease
15.1 Oral Manifestations of Systemic Disease 15.2 Orofacial Pain and Temporomandibular Disorders 15.3 Dry Mouth, Altered Taste and Halitosis
16 Chapter 16: Infection Prevention and Control
16.1 The Decontamination Cycle, Sterilization and Waterlines 16.2 Routes of Transmission and Blood-Borne Viruses
17 Chapter 17: Dental Materials
17.1 Dental Amalgam: Metallurgy and UK Regulation 17.2 Resin Composites: Chemistry and Placement 17.3 Dental Adhesive Systems 17.4 Acid Etching, the Hybrid Layer and MMP Degradation 17.5 Glass Ionomer Cements, RMGICs and Compomers 17.6 Impression Materials and Digital Scanning 17.7 Luting Cements and Adhesive Conditioning Protocols 17.8 Dental Ceramics and Cast Alloys 17.9 Gypsum Products, Waxes and Denture Base Polymers
18 Chapter 18: Behavioural Sciences Relevant to Oral Health Care
18.1 Health Behaviour Models and Behaviour Change 18.2 Dental Anxiety and Phobia 18.3 Psychosocial and Sociological Determinants of Oral Health
19 Chapter 19: Patient Assessment and Diagnosis
19.1 History Taking and Clinical Examination 19.2 Special Investigations and Reaching a Diagnosis
20 Chapter 20: Treatment Planning and Risk-Based Care
20.1 Treatment Planning and Sequencing 20.2 Risk Assessment, Recall Intervals and Preventive Planning
21 Chapter 21: Cariology and Caries Risk Assessment
21.1 Caries Pathogenesis and the Stephan Curve 21.2 Histopathology of Enamel and Dentinal Caries 21.3 Caries Diagnosis, ICDAS and Risk Assessment
22 Chapter 22: Operative Dentistry and Minimal Intervention
22.1 Minimal Intervention and Selective Caries Removal 22.2 Pulp Vitality Assessment and Biological Pulp Capping 22.3 Cavity Design, the C-Factor and Margin Geometry
23 Chapter 23: Endodontics
23.1 Pulp Histology and the Low-Compliance Environment 23.2 Pulpal Neurophysiology and Dentine Hypersensitivity 23.3 Pulpal and Periapical Diagnostic Terminology 23.4 Endodontic Diagnostic Testing 23.5 Access Cavity Design and Canal Configurations 23.6 Working Length Determination and Canal Preparation 23.7 Chemical Disinfection and Irrigant Activation 23.8 Medicaments, Obturation Materials and Techniques 23.9 Restoring Endodontically Treated Teeth 23.10 Endodontic Emergencies, Cracked Teeth and Root Fracture
24 Chapter 24: Periodontology
24.1 The 2018 Classification and Periodontal Health 24.2 Plaque-Induced and Non-Plaque-Induced Gingival Disease 24.3 Staging and Grading Periodontitis 24.4 Peri-Implant Disease and Systemic Risk Factors 24.5 The Basic Periodontal Examination 24.6 Simplified BPE in Children and Full Periodontal Charting 24.7 Furcation Involvement, Mobility and Occlusal Trauma 24.8 The BSP Stepwise Treatment Framework 24.9 Periodontal Instrumentation and Healing 24.10 Re-Evaluation, Endpoints and Periodontal Surgery 24.11 Crown Lengthening, Supracrestal Attachment and Supportive Care
25 Chapter 25: Fixed Prosthodontics
25.1 Biomechanical Principles of Tooth Preparation 25.2 Margin Design and the Supracrestal Attachment 25.3 Bridge Design and Resin-Bonded Bridges 25.4 Gingival Retraction, Provisionals and Temporary Cements
26 Chapter 26: Removable Prosthodontics
26.1 Removable Partial Dentures: Classification, Design and Surveying 26.2 Complete Dentures: Principles, Impressions and Jaw Registration
27 Chapter 27: Paediatric Dentistry
27.1 Primary Tooth Anatomy and Caries Management Strategies 27.2 Preformed Metal Crowns and the Hall Technique 27.3 Pulp Therapy in Primary Teeth 27.4 Extractions in the Primary Dentition 27.5 Non-Pharmacological Behaviour Management 27.6 Inhalation Sedation in Paediatric Dentistry 27.7 The Developing Dentition and Space Management 27.8 Serial Extraction and Non-Nutritive Sucking Habits
28 Chapter 28: Dental Traumatology
28.1 Trauma Assessment and Fractures of Permanent Teeth 28.2 Luxation Injuries, Avulsion and Replantation 28.3 Primary Tooth Trauma and Splinting Specifications
29 Chapter 29: Orthodontics
29.1 Extraoral Orthodontic Assessment 29.2 Intraoral Occlusal Assessment 29.3 Skeletal Pattern and Cephalometric Analysis 29.4 IOTN and NHS Treatment Eligibility 29.5 Upper Removable Appliances 29.6 Functional and Fixed Appliances 29.7 Biology of Orthodontic Tooth Movement 29.8 Orthodontic Risks and Retention
30 Chapter 30: Oral Surgery
30.1 Exodontia Biomechanics and Instrument Selection 30.2 Surgical Flap Design, Bone Removal and Suturing 30.3 Third Molar Surgery and NICE Guidance 30.4 Dry Socket and Oroantral Communication 30.5 Odontogenic Infection and Fascial Space Spread
31 Chapter 31: Oral Medicine
31.1 Recurrent Aphthous Stomatitis 31.2 Oral Candidiasis 31.3 Viral Oral Infections 31.4 Reactive Soft Tissue Lesions and the Epulides 31.5 Oral Potentially Malignant Disorders 31.6 Oral Squamous Cell Carcinoma, Urgent Referral and Biopsy
32 Chapter 32: Oral Pathology
32.1 Odontogenic and Non-Odontogenic Cysts 32.2 Odontogenic Tumours 32.3 Obstructive and Reactive Salivary Gland Disease 32.4 Salivary Gland Neoplasms
33 Chapter 33: Therapeutics and Prescribing
33.1 Local Anaesthetic Chemistry and Mechanism of Action 33.2 UK Local Anaesthetic Formulations 33.3 Vasoconstrictors, Maximum Doses and Systemic Toxicity 33.4 Analgesics for Acute Dental Pain 33.5 Antimicrobial Stewardship and First-Line Regimens 33.6 Antifungal and Antiviral Therapeutics
34 Chapter 34: Medical Emergencies in Dental Practice
34.1 The ABCDE Approach and the Emergency Drug Kit 34.2 Anaphylaxis and Acute Coronary Syndrome 34.3 Hypoglycaemia, Acute Asthma and Seizures 34.4 Syncope, Adrenal Crisis, Choking and Resuscitation
35 Chapter 35: Dental Radiology and Radiation Protection
35.1 Radiation Physics, Filtration and Collimation 35.2 Intraoral, Bitewing and Occlusal Projections 35.3 Dental Panoramic Tomography: Principles, Positioning and Errors 35.4 Lateral Cephalometry and Cone Beam CT 35.5 Systematic Reporting and Radiographic Caries Diagnosis 35.6 Radiology of Periodontal Bone Loss and Jaw Lesions 35.7 Radiographic Quality Assurance 35.8 IRR17 and IR(ME)R 2017
36 Chapter 36: Special Care Dentistry and Conscious Sedation
36.1 Special Care Dentistry, Risk Stratification and Sedation Principles 36.2 Inhalation Sedation with Nitrous Oxide 36.3 Intravenous Sedation with Midazolam 36.4 Oral Sedation and General Anaesthesia Referral
37 Chapter 37: Dental Public Health
37.1 Delivering Better Oral Health and the Fluoride Toolkit 37.2 Oral Health Epidemiology and Indices 37.3 Inequalities, Water Fluoridation and Population Prevention 37.4 NHS Dental Services, Access and Commissioning
38 Chapter 38: Communication and Interpersonal Skills
38.1 Patient Communication and Shared Decision-Making 38.2 Breaking Bad News, Complaints and the Duty of Candour 38.3 Referrals, Records and Communication with the Team
39 Chapter 39: Consent and Capacity
39.1 Valid Consent and the Montgomery Standard 39.2 The Mental Capacity Act 2005 39.3 Best Interests Decisions and Lasting Power of Attorney 39.4 Consent in Children and Young People 39.5 Safeguarding Children and Vulnerable Adults 39.6 Confidentiality, Data Protection and Lawful Disclosure
40 Chapter 40: Clinical Professionalism and the GDC
40.1 The General Dental Council and Standards Principles 1 to 4 40.2 GDC Standards: Principles 5 to 9 40.3 The GDC Fitness to Practise Process 40.4 Clinical Governance and the Audit Cycle
41 Chapter 41: Health and Safety Law in Dental Practice
41.1 Health and Safety Legislation, COSHH, RIDDOR and Sharps
42 Chapter 42: Self-Management and Professional Development
42.1 Enhanced CPD, Lifelong Learning and Reflective Practice 42.2 Managing Time, Stress and Clinical Wellbeing 42.3 Leadership, Delegation and Practice Management
13.1 Diabetes Mellitus and the Periodontal Axis
Key Takeaways Explain This Topic AI
HbA1c reflects average glycaemia over the preceding 8 to 12 weeks, the lifespan of the erythrocyte.
Diabetic patients should be seen in the morning, roughly 60 to 90 minutes after a normal meal and their usual medication.
Hypoglycaemia is defined as capillary blood glucose below 4.0 mmol/L, summarised as four is the floor.
A conscious hypoglycaemic patient receives 15 to 20 g of rapid-acting carbohydrate, repeated after 10 to 15 minutes if still below 4.0 mmol/L, then complex carbohydrate.
An unconscious or uncooperative hypoglycaemic patient receives 1 mg glucagon intramuscularly or subcutaneously and an ambulance call.
Last updated: September 2026
1. Diabetes Mellitus: Diagnostics, Perioperative Protocols, and the Periodontal Axis
Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. It is broadly categorized into:
Type 1 Diabetes Mellitus (T1DM): Characterized by autoimmune destruction of pancreatic beta-cells within the islets of Langerhans, leading to an absolute deficiency of endogenous insulin. It typically manifests in childhood or adolescence and carries a high risk of diabetic ketoacidosis (DKA).
Type 2 Diabetes Mellitus (T2DM): Characterized by progressive peripheral insulin resistance coupled with a compensatory, then declining, pancreatic beta-cell secretory defect. It accounts for > 90 % >90\% > 90% of cases and is strongly associated with central adiposity, physical inactivity, and metabolic syndrome.
Diagnostic Criteria per WHO and UK Practice
Diabetes mellitus is diagnosed based on venous plasma glucose concentrations or glycated haemoglobin ( H b A 1 c HbA_{1c} H b A 1 c ):
Diagnostic Parameter Normal Baseline Impaired Glycaemia (Pre-diabetes) Diabetes Mellitus Threshold
Fasting Plasma Glucose (FPG) < 6.1 mmol/L < 6.1\text{ mmol/L} < 6.1 mmol/L 6.1 − 6.9 mmol/L 6.1-6.9\text{ mmol/L} 6.1 − 6.9 mmol/L (Impaired Fasting Glucose) ≥ 7.0 mmol/L \ge 7.0\text{ mmol/L} ≥ 7.0 mmol/L
2-Hour Post-OGTT Glucose (75 g load) < 7.8 mmol/L < 7.8\text{ mmol/L} < 7.8 mmol/L 7.8 − 11.0 mmol/L 7.8-11.0\text{ mmol/L} 7.8 − 11.0 mmol/L (Impaired Glucose Tolerance) ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L
Random Plasma Glucose (with symptoms) N/A N/A ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L
Glycated Haemoglobin ( H b A 1 c HbA_{1c} H b A 1 c ) < 42 mmol/mol < 42\text{ mmol/mol} < 42 mmol/mol ( < 6.0 % < 6.0\% < 6.0% ) 42 − 47 mmol/mol 42-47\text{ mmol/mol} 42 − 47 mmol/mol ( 6.0 − 6.4 % 6.0-6.4\% 6.0 − 6.4% ) ≥ 48 mmol/mol \ge 48\text{ mmol/mol} ≥ 48 mmol/mol ( ≥ 6.5 % \ge 6.5\% ≥ 6.5% )
Glycated Haemoglobin ( H b A 1 c HbA_{1c} H b A 1 c ): IFCC vs DCCT Standards
H b A 1 c HbA_{1c} H b A 1 c reflects average glycaemic exposure over the preceding 8 to 12 weeks (the erythrocyte lifespan). Historically, H b A 1 c HbA_{1c} H b A 1 c was reported as a percentage according to the Diabetes Control and Complications Trial ( DCCT % ). In modern UK practice, results are reported in millimoles per mole ( mmol/mol ) according to the International Federation of Clinical Chemistry ( IFCC ): HbA 1 c (mmol/mol) = [ HbA 1 c (%) − 2.15 ] × 10.929 \text{HbA}_{1c}\text{ (mmol/mol)} = [\text{HbA}_{1c}\text{ (\%)} - 2.15] \times 10.929 HbA 1 c (mmol/mol) = [ HbA 1 c (%) − 2.15 ] × 10.929
Target for Well-Controlled Diabetes: 48 − 53 mmol/mol 48-53\text{ mmol/mol} 48 − 53 mmol/mol ( 6.5 − 7.0 % 6.5-7.0\% 6.5 − 7.0% ). Minor oral surgery and routine restorations proceed without added risk.
Moderate Control: 54 − 69 mmol/mol 54-69\text{ mmol/mol} 54 − 69 mmol/mol ( 7.1 − 8.5 % 7.1-8.5\% 7.1 − 8.5% ). Delayed soft tissue healing and increased susceptibility to infection; prophylactic measures indicated.
Poorly Controlled / Uncontrolled: > 69 mmol/mol > 69\text{ mmol/mol} > 69 mmol/mol ( > 8.5 % > 8.5\% > 8.5% ). Significant risk of perioperative infection, impaired collagen synthesis, and emergency metabolic crises. Defer extensive elective surgical procedures pending medical optimization.
Perioperative Dental Management of Diabetic Patients
Appointment Scheduling: Always schedule appointments in the morning , approximately 60 to 90 minutes after the patient has consumed their normal breakfast and administered their prescribed subcutaneous insulin or oral hypoglycaemic agents (e.g., metformin, gliclazide, SGLT2 inhibitors). Morning appointments align with peak cortisol and glucose levels, minimizing the risk of fasting-induced hypoglycaemia.
Dietary Confirmation: Confirm upon arrival that the patient has eaten their usual meal and taken their medication. Never perform dental treatment on a diabetic patient who has taken insulin but skipped breakfast.
Appointment Duration: Keep appointments brief and avoid procedures that extend into the patient's normal lunchtime, which disrupts metabolic scheduling.
Acute Hypoglycaemia: Recognition and Chairside Management
Hypoglycaemia is defined clinically as a blood glucose level falling below 4.0 mmol/L 4.0\text{ mmol/L} 4.0 mmol/L ( "four is the floor" ). It is the most common medical emergency encountered in diabetic patients in dental surgery. Blood Glucose < 4.0 mmol/L ("Four is the Floor")
│
├── Conscious, Cooperative Patient (Intact Swallowing Reflex):
- │ ├── Administer 15–20 g Rapid-Acting Carbohydrate (GlucoGel, 200 mL fruit juice, 4–5 glucotabs)
- │ ├── Wait 10–15 minutes, re-check blood glucose
- │ ├── If still < 4.0 mmol/L: Repeat 15–20 g rapid-acting carbohydrate
- │ └── Once > 4.0 mmol/L: Provide complex carbohydrate (biscuit, bread) to prevent relapse
- │
└── Unconscious, Convulsing, or Aggressive Patient (Impaired Swallowing):
- ├── Stop dental care, recline patient, maintain patent airway, administer high-flow oxygen
- ├── Administer 1 mg Glucagon IM or SC (anterolateral thigh / upper arm)
- ├── Alternatively, if IV access is established: 50–100 mL of 20% Glucose IV over 10 minutes
- └── Call 999 immediately
Signs and Symptoms:
Autonomic (Sympathetic surge, early): Diaphoresis (cold sweats), tremor, tachycardia, palpitations, anxiety, pallor, and intense hunger.
Neuroglycopenic (Cerebral glucose deprivation, late): Confusion, slurred speech, emotional lability, irrational or combative behaviour, visual disturbances, drowsiness, convulsions, and coma.
Conscious Patient Protocol: Stop treatment immediately. Administer 15 to 20 g of fast-acting oral carbohydrate (e.g., 150–200 mL pure orange juice, 4 to 5 jelly babies, 4 to 5 Glucotabs, or 1 to 2 tubes of 40% dextrose gel [GlucoGel] massaged into the buccal pouch). Wait 10 to 15 minutes, re-test blood glucose. If still < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L , repeat the rapid-acting carbohydrate. Once blood glucose recovers above 4.0 mmol/L 4.0\text{ mmol/L} 4.0 mmol/L , administer long-acting complex carbohydrates (two digestive biscuits, a slice of toast, or their scheduled meal) to replenish hepatic glycogen stores.
Unconscious Patient Protocol: Call 999 . Do not force liquids into the oral cavity. Lay the patient flat on their side in the recovery position, clear the airway, and administer high-flow oxygen. Administer 1 mg of Glucagon intramuscularly (IM) or subcutaneously (SC) (in children under 8 years or < 25 kg <25\text{ kg} < 25 kg , administer 0.5 mg). Glucagon stimulates hepatic glycogenolysis; response typically occurs within 5 to 10 minutes. If intravenous access is present, medical staff may administer 50 to 100 mL of 20% glucose IV (or 100 to 200 mL of 10% glucose IV) over 10 minutes.
The Bidirectional Relationship: Diabetes and Periodontal Disease
Periodontitis is recognized as the "sixth complication of diabetes". The interaction between the two diseases is biologically bidirectional:
Effect of Hyperglycaemia on the Periodontium: Chronic hyperglycaemia leads to the irreversible non-enzymatic glycation of proteins, forming Advanced Glycation End-products (AGEs) . AGEs bind to their specific receptor ( RAGE ) on endothelial cells, monocytes, and macrophages. This AGE-RAGE interaction activates nuclear factor kappa B ( N F − κ B NF-\kappa B NF − κ B ), triggering a hyper-inflammatory phenotype that secretes excessive quantities of pro-inflammatory cytokines ( I L − 1 β IL-1\beta I L − 1 β , T N F − α TNF-\alpha TNF − α , I L − 6 IL-6 I L − 6 ). Concurrently, polymorphonuclear leukocyte (neutrophil) chemotaxis and phagocytosis are impaired, microvascular basement membranes thicken (microangiopathy, reducing tissue perfusion and oxygen delivery), and the RANKL/OPG ratio surges, driving accelerated, severe alveolar bone loss and periodontal attachment breakdown.
Effect of Periodontitis on Glycaemic Control: Severe chronic periodontitis represents an extensive, ulcerated subgingival surface area (equivalent to the palm of an adult hand). Chronic bacteremia and systemic entry of periodontal cytokines ( T N F − α TNF-\alpha TNF − α and I L − 6 IL-6 I L − 6 ) induce systemic inflammation and promote peripheral insulin resistance by impairing insulin receptor substrate-1 (IRS-1) phosphorylation in skeletal muscle and adipose tissue. Consequently, severe periodontitis significantly worsens glycaemic control in diabetic patients.
Clinical Intervention Evidence: Landmark randomized controlled trials and Cochrane systematic reviews demonstrate that successful non-surgical periodontal instrumentation and resolution of periodontal inflammation produces a clinically meaningful reduction in glycated haemoglobin of approximately 3 − 4 mmol/mol 3-4\text{ mmol/mol} 3 − 4 mmol/mol ( 0.3 − 0.4 % 0.3-0.4\% 0.3 − 0.4% ) at 3 to 4 months post-treatment—an efficacy comparable to adding a second oral hypoglycaemic drug.